Core Insights - CalciMedica Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies targeting calcium release-activated calcium (CRAC) channels for inflammatory and immunologic diseases [1][2] - The company will present at the 30th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference, highlighting the role of ORAI-1 in acute kidney injury (AKI) [1][2] Company Overview - CalciMedica's proprietary technology aims to inhibit CRAC channels to modulate immune responses and protect against tissue cell injury, potentially addressing life-threatening conditions without approved therapies [2] - The lead product candidate, Auxora™, has shown positive clinical results in multiple completed efficacy trials [2] - Ongoing clinical trials include a Phase 2b trial for acute pancreatitis (CARPO), a Phase 2 trial for COVID pneumonia (CARDEA), and a Phase 2 trial for acute kidney injury with respiratory failure (KOURAGE) [2] - The company also supports a Phase 1/2 trial in pediatric patients with asparaginase-induced pancreatic toxicity (CRSPA) [2] - CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, California [2]
CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference